Skip to content

Randomized Controlled Multicenter Clinical Trial of Sanzi Huangshi No.1 Pill in the Treatment of Pre-MDS

Randomized Controlled Multicenter Clinical Trial of Sanzi Huangshi No.1 Pill in the Treatment of Pre-MDS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064229
Enrollment
Unknown
Registered
2022-09-30
Start date
2022-09-30
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndrome

Interventions

Control group :supportive care
Treatment group :Sanzi Huangshi No.1 Pill Combined Supportive Therapy

Sponsors

Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The study was excluded if any of the following criteria were met: 1. Patients diagnosed with CHIP; 2. Patients with other hematologic or non-hematologic tumors; 3. Combined with more serious cardiovascular and cerebrovascular, liver, kidney and other organic diseases and peripheral neuropathy; 4. Pregnant or lactating women; 5. Patients with mental illness who cannot cooperate with treatment; 6. Patients with Class A and Class B infectious diseases. 7. Patients with active hepatitis; 8. Patients who are participating in other clinical trials; 9. Patients with poor compliance.

Exclusion criteria

Exclusion criteria: The study was excluded if any of the following criteria were met: 1. Patients diagnosed with CHIP; 2. Patients with other hematologic or non-hematologic tumors; 3. Combined with more serious cardiovascular and cerebrovascular, liver, kidney and other organic diseases and peripheral neuropathy; 4. Pregnant or lactating women; 5. Patients with mental illness who cannot cooperate with treatment; 6. Patients with Class A and Class B infectious diseases. 7. Patients with active hepatitis; 8. Patients who are participating in other clinical trials; 9. Patients with poor compliance.

Design outcomes

Primary

MeasureTime frame
Blood routine;Blood cell production assay;Tumor-related indicators;Tumor Microenvironment Detection;Bone marrow biopsy;

Secondary

MeasureTime frame
Arsenic concentrations in blood;Urine routine;Fecal routine;Liver function;Kidney function;electrocardiogram;

Countries

China

Contacts

Public ContactJiahui Lu

Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

lujiahui73@163.com+86 13601759004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026